Profile data is unavailable for this security.
About the company
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.
- Revenue in USD (TTM)79.57k
- Net income in USD-18.38m
- Incorporated2010
- Employees8.00
- LocationInhibikase Therapeutics Inc3350 Riverwood Parkway Se, Suite 1900ATLANTA 30339United StatesUSA
- Phone+1 (678) 392-3419
- Fax+1 (302) 655-5049
- Websitehttps://www.inhibikase.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nascent Biotech Inc | 0.00 | -1.92m | 8.08m | -- | -- | -- | -- | -- | -0.012 | -0.012 | 0.00 | -0.003 | 0.00 | -- | -- | -- | -1,256.81 | -708.50 | -- | -- | -- | -- | -- | -589.83 | -- | -- | -- | -- | -- | -- | 25.47 | -- | -- | -- |
Mustang Bio Inc | 0.00 | -32.06m | 8.27m | 80.00 | -- | -- | -- | -- | -2.91 | -2.91 | 0.00 | -0.2384 | 0.00 | -- | -- | 0.00 | -170.53 | -70.02 | -727.24 | -79.98 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 33.44 | -- | -60.75 | -- |
Silexion Therapeutics Corp | 0.00 | -523.87k | 8.50m | 0.00 | -- | 1.33 | -- | -- | -0.1403 | -0.1403 | 0.00 | 0.6559 | 0.00 | -- | -- | -- | -3.13 | -- | -3.77 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.96 | -- | -- | -- |
Carmell Corp | 12.32k | -15.97m | 8.60m | 9.00 | -- | -- | -- | 698.09 | -1.53 | -1.44 | 0.0006 | -0.0656 | -- | -- | -- | 1,368.89 | -- | -- | -- | -- | 58.73 | -- | -129,263.60 | -- | 0.6901 | -- | -- | -- | -- | -- | -75.70 | -- | -- | -- |
ABVC Biopharma Inc | 136.40k | -11.37m | 8.64m | 16.00 | -- | 1.01 | -- | 63.36 | -1.78 | -1.78 | 0.0172 | 0.6882 | 0.0114 | -- | 0.4213 | 8,525.00 | -99.79 | -103.38 | -197.79 | -231.54 | -24.11 | 76.25 | -8,762.13 | -2,019.89 | -- | -2.50 | 0.1873 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
Soligenix Inc | 494.62k | -7.04m | 8.71m | 13.00 | -- | 1.70 | -- | 17.61 | -9.58 | -9.58 | 0.6152 | 2.25 | 0.0418 | -- | 8.70 | 38,047.69 | -59.45 | -75.40 | -121.64 | -154.32 | 8.75 | 22.83 | -1,423.81 | -620.02 | -- | -- | 0.4421 | -- | -11.54 | -30.67 | 55.50 | -- | -- | -- |
Calidi Biotherapeutics Inc | 0.00 | -24.92m | 8.81m | 41.00 | -- | -- | -- | -- | -5.41 | -5.41 | 0.00 | -1.82 | 0.00 | -- | -- | 0.00 | -279.89 | -- | -- | -- | -- | -- | -- | -- | -- | -27.58 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
Viracta Therapeutics Inc | 0.00 | -45.34m | 8.82m | 40.00 | -- | -- | -- | -- | -1.16 | -1.16 | 0.00 | 0.0678 | 0.00 | -- | -- | 0.00 | -83.82 | -86.35 | -140.98 | -106.38 | -- | -- | -- | -11,853.94 | -- | -59.78 | 0.8753 | -- | -- | -- | -3.78 | -- | -- | -- |
Molecular Templates Inc | 25.47m | -15.63m | 8.89m | 62.00 | -- | 1.25 | -- | 0.349 | -2.70 | -2.70 | 4.24 | 1.08 | 0.8189 | -- | 47.65 | 410,806.40 | -50.24 | -51.78 | -113.26 | -73.14 | -- | -- | -61.35 | -228.33 | -- | -- | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
BioCardia Inc | 428.00k | -8.56m | 8.89m | 16.00 | -- | -- | -- | 20.78 | -5.40 | -5.40 | 0.2636 | -0.9233 | 0.0923 | -- | 6.85 | 26,750.00 | -184.48 | -107.34 | -1,075.25 | -154.17 | -- | -- | -1,999.77 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
Inhibikase Therapeutics Inc | 79.57k | -18.38m | 8.96m | 8.00 | -- | 1.70 | -- | 112.57 | -2.93 | -2.93 | 0.0126 | 0.7063 | 0.0051 | -- | -- | 9,946.25 | -117.93 | -66.49 | -148.63 | -85.55 | -- | -- | -23,102.16 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
Portage Biotech Inc | 0.00 | -71.08m | 9.15m | 7.00 | -- | 3.64 | -- | -- | -68.81 | -68.81 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -137.29 | -30.53 | -143.21 | -40.02 | -- | -- | -- | -- | -- | -- | 0.02 | -- | -- | -- | 27.98 | -- | -- | -- |
Kintara Therapeutics Inc | 0.00 | -9.51m | 9.63m | 2.00 | -- | -- | -- | -- | -4.08 | -4.08 | 0.00 | 0.1071 | 0.00 | -- | -- | 0.00 | -131.55 | -220.94 | -185.60 | -329.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 40.24 | -- | 78.93 | -- |
Plus Therapeutics Inc (USA) | 5.51m | -13.23m | 9.67m | 20.00 | -- | -- | -- | 1.76 | -3.05 | -3.05 | 1.19 | -1.34 | 0.4336 | -- | -- | 275,450.00 | -104.14 | -59.18 | -- | -133.04 | -- | -- | -240.15 | -470.45 | -- | -4.17 | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
Kazia Therapeutics Ltd (ADR) | 15.35k | -13.93m | 9.67m | 12.00 | -- | 0.9028 | -- | 630.04 | -0.8448 | -0.8448 | 0.0008 | 0.3597 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
Oncotelic Therapeutics Inc | 70.00k | -1.24m | 9.75m | 22.00 | -- | 0.8041 | -- | 139.29 | -0.0031 | -0.0031 | 0.0002 | 0.0299 | 0.0023 | -- | 3.69 | 3,181.82 | -5.02 | -25.03 | -11.26 | -48.76 | -- | -- | -2,147.66 | -1,692.93 | -- | -0.5167 | 0.5228 | -- | -- | -- | -255.12 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 30 Jun 2024 | 589.58k | 7.90% |
William Blair Investment Management LLCas of 30 Jun 2024 | 116.12k | 1.56% |
Citadel Securities LLCas of 30 Jun 2024 | 37.90k | 0.51% |
Geode Capital Management LLCas of 30 Jun 2024 | 37.33k | 0.50% |
Renaissance Technologies LLCas of 30 Jun 2024 | 20.82k | 0.28% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 16.72k | 0.22% |
Timber Point Capital Management LLCas of 30 Jun 2024 | 11.00k | 0.15% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 10.08k | 0.14% |
Tower Research Capital LLCas of 30 Jun 2024 | 5.74k | 0.08% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 1.67k | 0.02% |